South Korean biotech firm L&C Bio has announced plans to market a new injectable skin booster designed to restore facial volume. The product is derived from donated human fat, a technology the company has been developing for approximately five years. CEO Lee Whan Chul stated that the firm intends to capitalize on the growing demand for cosmetic procedures among individuals experiencing 'Ozempic face,' a term used to describe the sagging or gaunt facial appearance that can occur following the use of popular weight-loss medications.

L&C Bio has previously established itself in the K-beauty market by utilizing donated human tissue for aesthetic skin boosters. The company currently holds patents on the proprietary technology used to process this donor material. While the company views this as a significant growth opportunity, the product represents a niche intersection between medical tissue donation and the cosmetic beauty industry. The move highlights how the biotech sector is increasingly aligning its product development with the secondary effects of the global surge in GLP-1 weight-loss drug usage. As of now, the company is positioning this as the next potential trend in the South Korean beauty market, banking on the idea that consumers will seek medical interventions to reverse the aesthetic consequences of rapid weight reduction.